Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis.

IF 4.8 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-30 DOI:10.1080/14760584.2025.2536087

Anke L Stuurman, Joshua Enxing, Aura V Gutiérrez, Christen M Gray, Ingrid T Sepúlveda-Pachón, Egbe Ubamadu, Allyn Bandell, Sylvia Taylor, Georges El Azzi, Wilhelmine Meeraus

{"title":"Real-world effectiveness of live attenuated influenza vaccines (LAIV) and inactivated influenza vaccines (IIV) in children from 2003 to 2023: a systematic literature review and network meta-analysis.","authors":"Anke L Stuurman, Joshua Enxing, Aura V Gutiérrez, Christen M Gray, Ingrid T Sepúlveda-Pachón, Egbe Ubamadu, Allyn Bandell, Sylvia Taylor, Georges El Azzi, Wilhelmine Meeraus","doi":"10.1080/14760584.2025.2536087","DOIUrl":null,"url":null,"abstract":"Introduction: Circulating influenza strains, vaccine effectiveness (VE), and vaccine recommendations vary over time. A systematic literature review (SLR), random effects meta-analysis (REMA), and network meta-analysis (NMA) estimated absolute VE (aVE) and relative VE (rVE) of LAIV and IIV in children/adolescents from initial LAIV approval in 2003.Methods: Northern Hemisphere studies (2003-2023) with children ≤19 yrs were included. A modified Newcastle-Ottawa Scale assessed risk-of-bias. REMA estimated aVE and three-node NMA (LAIV-IIV-unvaccinated) estimated rVE over three periods: 2003-04 to 2008-09 (pre-2009 A(H1N1) pandemic); 2010-11 to 2016-17 (post-2009 pandemic); 2017-18 to 2022-23 (post-LAIV strain-selection optimization).Results: One hundred and nine studies included. aVE of LAIV and IIV against any influenza was similar (~50%) in each period. Effectiveness of LAIV vs. IIV against influenza types/subtypes was comparable except (1) greater effectiveness with IIV for A(H1N1) in 2010-11 to 2016-17 (rVE -46% [95% CI: -57, -33]); (2) greater effectiveness with LAIV for influenza B in 2017-18 to 2022-23 (rVE 196% [95% CI: 73, 406]). In 2017-18 to 2022-23, effectiveness of LAIV and IIV against A(H1N1) was similar (rVE 10% [95% CI: -35, 87]).Conclusions: LAIV and IIV have demonstrated comparable effectiveness against any influenza in children.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"703-725"},"PeriodicalIF":4.8000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2536087","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Circulating influenza strains, vaccine effectiveness (VE), and vaccine recommendations vary over time. A systematic literature review (SLR), random effects meta-analysis (REMA), and network meta-analysis (NMA) estimated absolute VE (aVE) and relative VE (rVE) of LAIV and IIV in children/adolescents from initial LAIV approval in 2003.

Methods: Northern Hemisphere studies (2003-2023) with children ≤19 yrs were included. A modified Newcastle-Ottawa Scale assessed risk-of-bias. REMA estimated aVE and three-node NMA (LAIV-IIV-unvaccinated) estimated rVE over three periods: 2003-04 to 2008-09 (pre-2009 A(H1N1) pandemic); 2010-11 to 2016-17 (post-2009 pandemic); 2017-18 to 2022-23 (post-LAIV strain-selection optimization).

Results: One hundred and nine studies included. aVE of LAIV and IIV against any influenza was similar (~50%) in each period. Effectiveness of LAIV vs. IIV against influenza types/subtypes was comparable except (1) greater effectiveness with IIV for A(H1N1) in 2010-11 to 2016-17 (rVE -46% [95% CI: -57, -33]); (2) greater effectiveness with LAIV for influenza B in 2017-18 to 2022-23 (rVE 196% [95% CI: 73, 406]). In 2017-18 to 2022-23, effectiveness of LAIV and IIV against A(H1N1) was similar (rVE 10% [95% CI: -35, 87]).

Conclusions: LAIV and IIV have demonstrated comparable effectiveness against any influenza in children.

查看原文本刊更多论文

2003年至2023年儿童流感减毒活疫苗（LAIV）和灭活疫苗（iv）的实际有效性：系统文献综述和网络荟萃分析

简介：流行的流感毒株、疫苗有效性（VE）和疫苗建议随时间而变化。通过系统文献综述（SLR）、随机效应荟萃分析（REMA）和网络荟萃分析（NMA）估算了2003年LAIV批准以来儿童/青少年LAIV和IIV的绝对VE （aVE）和相对VE （rVE）。方法：纳入北半球研究（2003-2023），儿童≤19岁。修改后的纽卡斯尔-渥太华量表评估偏倚风险。在2003-04年至2008-09年（2009年前甲型H1N1流感大流行）这三个时期，REMA估计的流感病毒感染率和三节点流感病毒感染率（laiv - iv -未接种疫苗）估计的流感病毒感染率；2010-11至2016-17（2009年后大流行）；2017-18 ~ 2022-23（后laiv菌株选择优化）。结果：纳入109项研究。LAIV和IIV在各时期对流感的免疫应答率相似（~50%）。LAIV与IIV对流感类型/亚型的有效性具有可比性，除了：(1)2010-11年至2016-17年，IIV对甲型H1N1流感的有效性更高（rVE -46% [95% CI: -57, -33]）；(2) 2017-18年至2022-23年，LAIV治疗乙型流感的有效性更高（rVE为196% [95% CI: 73,406]）。在2017-18年至2022-23年期间，LAIV和iv对甲型H1N1流感的有效性相似（rVE为10% [95% CI: - 35,87]）。结论：LAIV和iv对儿童流感的疗效相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.